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Objectives:  A recent transposon 
mutagenesis screen has identified the 
Zmiz1 gene as a new potential 
oncogene in carcinomas of the skin.  It 
is well known that mutations of the p53 
tumor suppressor gene are the most 
common genetic alterations in epithelial 
ovarian cancer.  Previous studies have 
shown that Zmiz1 appears to 
transcriptionally regulate the p53 gene. 
There are no studies that evaluate 
Zmiz1 expression and alterations in the 
p53 gene in gynecologic malignancies, 
specifically epithelial ovarian cancer.  
We hypothesize Zmiz1 expression is 
elevated in epithelial ovarian tumors and 
there is an interaction between Zmiz1 
and the p53 tumor suppressor gene in 
ovarian tumors.  
Methods:  A retrospective chart review 
was performed to identify patients 
diagnosed with epithelial ovarian 
cancer.  Data collected included clinico-
pathologic factors, patient follow-up and 
mortality.  Zmiz1 staining and p53 
sequencing were performed on all 
patients.  Statistical analyses included 
chi-square analysis and the binomial 
test for clinical and pathologic factors.  
The log rank test was used to evaluate 
survival analysis. 
Results:  Included in the analysis were 
sixty-one patients diagnosed with 
epithelial ovarian cancer.  
Immunostaining for the Zmiz1 protein 
was performed with the following 
results: 17 (28%) tumors were positive, 
11 (18%) tumors had equivocal staining, 
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and 33 (54%) tumors were negative.  All 
of the benign ovarian specimens were 
negative for Zmiz1 immunostaining.  Of 
the tumors with positive Zmiz1 staining, 
13/17 (76%) had p53 gene mutations 
(p=0.03).  The majority of patients 
without p53 mutations stained negative 
for Zmiz1 (p=0.005).  The overall 
survival for patients with Zmiz1 positive 
staining was 37% vs. 52% for patients 
with negative staining (p=0.10). 
 
 
Conclusions:  Zmiz1 staining is 
elevated in patients with epithelial 
ovarian cancer.  Tumors that are Zmiz1 
positive are associated with mutations of 
the p53 gene.  Zmiz1 overexpression 
may be associated with decreased 
survival in patients with epithelial 
ovarian cancer.  Additional studies are 
needed to more clearly determine the 
role of Zmiz1 in patients with epithelial 
ovarian cancer. 
 
 
 
